These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 5808572)

  • 21. Predictive value of the probenecid test for the effect of L-DOPA therapy in Parkinson's disease.
    Lakke JP; Korf J; Van Praag HM; Schut T
    Nat New Biol; 1972 Apr; 236(68):208-9. PubMed ID: 4553111
    [No Abstract]   [Full Text] [Related]  

  • 22. Serial determinations of homovanillinic acid in the cerebrospinal fluid of Parkinson patients treated with L-dopa.
    Bertler A; Jeppsson PG; Nordgren L; Rosengren E
    Acta Neurol Scand; 1971; 47(4):393-402. PubMed ID: 4941731
    [No Abstract]   [Full Text] [Related]  

  • 23. Methyldopahydrazine as an adjunct to L-dopa therapy in parkinsonism.
    Chase TN; Watanabe AM
    Neurology; 1972 Apr; 22(4):384-92. PubMed ID: 5062828
    [No Abstract]   [Full Text] [Related]  

  • 24. The effect of L-dopa on monoamine metabolites in Parkinson's disease.
    van Woert MH; Bowers MB
    Experientia; 1970; 26(2):161-3. PubMed ID: 5308739
    [No Abstract]   [Full Text] [Related]  

  • 25. Levodopa.
    Lancet; 1971 Sep; 2(7723):533. PubMed ID: 4105672
    [No Abstract]   [Full Text] [Related]  

  • 26. Responses of the urinary excretion of homovanillic acid and of 5-hydroxy-indol-acetic acid to treatment with L-dopa and amantadine.
    Molnár G; Fodor A
    Ther Hung; 1973; 21(1):35-40. PubMed ID: 4792890
    [No Abstract]   [Full Text] [Related]  

  • 27. Absence of response to levodopa in Parkinson's disease.
    Mones RJ
    JAMA; 1971 Aug; 217(9):1245. PubMed ID: 5109470
    [No Abstract]   [Full Text] [Related]  

  • 28. On the relationship between L-DOPA therapy and CSF monoamine metabolites in Parkinson's disease.
    Casati C; Agnoli A; Jori A; Dolfini E
    Z Neurol; 1973 Apr; 204(2):149-54. PubMed ID: 4121468
    [No Abstract]   [Full Text] [Related]  

  • 29. The metabolism of orally administered L-dopa in Parkinson patients.
    Cote LJ; Cohen G; Yahr MD
    Trans Am Neurol Assoc; 1971; 96():222-3. PubMed ID: 5159086
    [No Abstract]   [Full Text] [Related]  

  • 30. The present status of levodopa and future approaches to therapy.
    Mones RJ
    Mt Sinai J Med; 1972; 39(3):279-86. PubMed ID: 4537267
    [No Abstract]   [Full Text] [Related]  

  • 31. Urinary excretion of dopamine and homovanillic acid during L-dopa treatment of Parkinson's disease.
    Streifler M; Vardi Y; Kesten M; Oberman Z; Herzberg M
    Isr J Med Sci; 1972 May; 81(5):597-601. PubMed ID: 5042950
    [No Abstract]   [Full Text] [Related]  

  • 32. The concentration of homovanillic and 5-hydroxyindoleacetic acids in ventricular and lumbar CSF. Studies in patients with extrapyramidal disorders, epilepsy, and other diseases.
    Papeschi R; Molina-Negro P; Sourkes TL; Erba G
    Neurology; 1972 Nov; 22(11):1151-9. PubMed ID: 4263829
    [No Abstract]   [Full Text] [Related]  

  • 33. L-Dopa for Parkinsonism.
    Cotzias GC
    N Engl J Med; 1968 Mar; 278(11):630. PubMed ID: 5637779
    [No Abstract]   [Full Text] [Related]  

  • 34. Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease.
    Muenter MD; Sharpless NS; Tyce GM
    Mayo Clin Proc; 1972 Jun; 47(6):389-95. PubMed ID: 5041685
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment of Parkinson's disease with amantadine and L-Dopa.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1972; 7(4):228-40. PubMed ID: 4556618
    [No Abstract]   [Full Text] [Related]  

  • 36. Catecholamine metabolism during oral administration of levodopa.
    Hinterberger H; Andrews CJ
    Arch Neurol; 1972 Mar; 26(3):245-52. PubMed ID: 5061285
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of parkinsonism by amantadine and levodopa.
    Mawdsley C; Williams IR; Pullar IA; Davidson DL; Kinloch NE
    Clin Pharmacol Ther; 1972; 13(4):575-83. PubMed ID: 4557584
    [No Abstract]   [Full Text] [Related]  

  • 38. How does L-dopa work in parkinsonism?
    Sandler M
    Lancet; 1971 Apr; 1(7703):784. PubMed ID: 4101278
    [No Abstract]   [Full Text] [Related]  

  • 39. [L-Dopa in parkinsonism, myth or reality].
    Henry P
    Bord Med; 1970 Feb; 3(2):393-7. PubMed ID: 5425873
    [No Abstract]   [Full Text] [Related]  

  • 40. Metabolism and clinical assessment of L-dopa in parkinsonism.
    Ericsson AD; McCann D; Sharpless N; Reveno W
    Neurology; 1970 Apr; 20(4):402. PubMed ID: 4935027
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.